Exact Mass: 1026.4058

Exact Mass Matches: 1026.4058

Found 23 metabolites which its exact mass value is equals to given mass value 1026.4058, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Bromelain

N-{5-[(5-{[4,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl]oxy}-3-acetamido-4-hydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]-2-hydroxy-6-(hydroxymethyl)-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl}acetamide

C39H66N2O29 (1026.3751)


   
   

mithramycin SA|MTM SA

mithramycin SA|MTM SA

C49H70O23 (1026.4308)


   

ManXylManGlcNAcFucGlcNAc

ManXylManGlcNAcFucGlcNAc

C39H66N2O29 (1026.3751)


[Chemical] Source; carrot glycoprotein

   

Demycarosyl-mithramycin

Demycarosyl-mithramycin

C49H70O23 (1026.4308)


   

Carbohydrate moiety of bromelain

Carbohydrate moiety of bromelain

C39H66N2O29 (1026.3751)


COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Fucalpha1-3[Manalpha1-3(Xylbeta1-2)Manbeta1-4GlcNAcbeta]1-4GlcNAcbeta

Fucalpha1-3[Manalpha1-3(Xylbeta1-2)Manbeta1-4GlcNAcbeta]1-4GlcNAcbeta

C39H66N2O29 (1026.3751)


   

Xylf(b1-2)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)]GlcNAc

Xylf(b1-2)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)]GlcNAc

C39H66N2O29 (1026.3751)


   

Fucalpha1-6[Manalpha1-3(Xylbeta1-2)Manbeta1-4GlcNAcbeta1-4]GlcNAcbeta

Fucalpha1-6[Manalpha1-3(Xylbeta1-2)Manbeta1-4GlcNAcbeta1-4]GlcNAcbeta

C39H66N2O29 (1026.3751)


   

Xyl(b1-2)[Man(b1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)]b-GlcNAc

Xyl(b1-2)[Man(b1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)]b-GlcNAc

C39H66N2O29 (1026.3751)


   

Xyl(b1-2)[Man(a1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(b1-3)]b-GlcNAc

Xyl(b1-2)[Man(a1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(b1-3)]b-GlcNAc

C39H66N2O29 (1026.3751)


   

Xylf(b1-2)[Fuc(a1-3)][Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc

Xylf(b1-2)[Fuc(a1-3)][Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc

C39H66N2O29 (1026.3751)


   

Xyl(b1-2)[Man(b1-3)]Man(b1-4)GlcNAc(a1-4)[Fuc(b1-3)]b-GlcNAc

Xyl(b1-2)[Man(b1-3)]Man(b1-4)GlcNAc(a1-4)[Fuc(b1-3)]b-GlcNAc

C39H66N2O29 (1026.3751)


   

Xylf(b1-2)[Fuc(a1-3)][Man(a1-6)]Man(b1-4)GlcNAc(b1-4)b-GlcNAc

Xylf(b1-2)[Fuc(a1-3)][Man(a1-6)]Man(b1-4)GlcNAc(b1-4)b-GlcNAc

C39H66N2O29 (1026.3751)


   

Xyl(b1-2)[Fuc(a1-3)][Man(a1-6)]Man(b1-4)GlcNAc(b1-4)b-GlcNAc

Xyl(b1-2)[Fuc(a1-3)][Man(a1-6)]Man(b1-4)GlcNAc(b1-4)b-GlcNAc

C39H66N2O29 (1026.3751)


   

Xylf(b1-2)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)]b-GlcNAc

Xylf(b1-2)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)]b-GlcNAc

C39H66N2O29 (1026.3751)


   

Fucalpha1-3[Manalpha1-3(Xylbeta1-2)Manbeta1-4GlcNAcbeta]1-4GlcNAc

Fucalpha1-3[Manalpha1-3(Xylbeta1-2)Manbeta1-4GlcNAcbeta]1-4GlcNAc

C39H66N2O29 (1026.3751)


   

L-Xyl(b1-2)[Man(a1-6)]L-Man(b1-4)GlcNAc(b1-4)[D-Fuc(a1-3)]b-GlcNAc

L-Xyl(b1-2)[Man(a1-6)]L-Man(b1-4)GlcNAc(b1-4)[D-Fuc(a1-3)]b-GlcNAc

C39H66N2O29 (1026.3751)


   

RNAIII-inhibiting peptide(TFA)

RNAIII-inhibiting peptide(TFA)

C47H57F3N10O13 (1026.4058)


RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

   

n-(5-{[4,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl]oxy}-4-hydroxy-2-({6-hydroxy-5-[(1-hydroxyethylidene)amino]-2-(hydroxymethyl)-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl}oxy)-6-(hydroxymethyl)oxan-3-yl)ethanimidic acid

n-(5-{[4,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl]oxy}-4-hydroxy-2-({6-hydroxy-5-[(1-hydroxyethylidene)amino]-2-(hydroxymethyl)-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl}oxy)-6-(hydroxymethyl)oxan-3-yl)ethanimidic acid

C39H66N2O29 (1026.3751)


   

n-[(3r,4r,5s,6r)-5-{[(2s,3r,4r,5s,6r)-5-{[(2s,3s,4s,5s,6r)-4,5-dihydroxy-6-({[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-2-hydroxy-6-(hydroxymethyl)-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]ethanimidic acid

n-[(3r,4r,5s,6r)-5-{[(2s,3r,4r,5s,6r)-5-{[(2s,3s,4s,5s,6r)-4,5-dihydroxy-6-({[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-2-hydroxy-6-(hydroxymethyl)-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]ethanimidic acid

C39H66N2O29 (1026.3751)


   

(3-{[4-({4-[(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy]-5-hydroxy-6-methyloxan-2-yl}oxy)-5-hydroxy-6-methyloxan-2-yl]oxy}-7-({4-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-5-hydroxy-6-methyloxan-2-yl}oxy)-5,10-dihydroxy-6-methyl-4-oxo-2,3-dihydro-1h-anthracen-2-yl)(methoxy)acetic acid

(3-{[4-({4-[(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy]-5-hydroxy-6-methyloxan-2-yl}oxy)-5-hydroxy-6-methyloxan-2-yl]oxy}-7-({4-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-5-hydroxy-6-methyloxan-2-yl}oxy)-5,10-dihydroxy-6-methyl-4-oxo-2,3-dihydro-1h-anthracen-2-yl)(methoxy)acetic acid

C49H70O23 (1026.4308)


   

(s)-[(2r,3s)-3-{[(2s,4r,5r,6r)-4-{[(2s,4r,5s,6r)-4-{[(2s,4s,5r,6r)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-5-hydroxy-6-methyloxan-2-yl]oxy}-5-hydroxy-6-methyloxan-2-yl]oxy}-7-{[(2s,4r,5r,6r)-4-{[(2s,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-5-hydroxy-6-methyloxan-2-yl]oxy}-5,10-dihydroxy-6-methyl-4-oxo-2,3-dihydro-1h-anthracen-2-yl](methoxy)acetic acid

(s)-[(2r,3s)-3-{[(2s,4r,5r,6r)-4-{[(2s,4r,5s,6r)-4-{[(2s,4s,5r,6r)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-5-hydroxy-6-methyloxan-2-yl]oxy}-5-hydroxy-6-methyloxan-2-yl]oxy}-7-{[(2s,4r,5r,6r)-4-{[(2s,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-5-hydroxy-6-methyloxan-2-yl]oxy}-5,10-dihydroxy-6-methyl-4-oxo-2,3-dihydro-1h-anthracen-2-yl](methoxy)acetic acid

C49H70O23 (1026.4308)